Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dynavax’s Heplisav Heads To Advisory Panel, But Will It Drudge Up Old Safety Issues?

This article was originally published in The Pink Sheet Daily

Executive Summary

Company says its hepatitis B vaccine, which had been placed on clinical hold at one point during its Phase III trials, will be discussed at a FDA advisory committee in November.

You may also be interested in...



Vaccine Adjuvant Heightens Panel’s Worries About Rare Adverse Events With Heplisav

FDA’s Vaccines and Related Biological Products Advisory Committee recommended 8 to 5 with one abstention that Dynavax acquire more safety data pre-licensure for its hepatitis B vaccine.

Dynavax Hepatitis B Vaccine Could Get Comparative Post-Market Autoimmunity Assessment

The observational study would look at Dynavax’s Heplisav and GlaxoSmithKline’s Energerix-B, according to FDA briefing materials for the Vaccines and Related Biological Products Advisory Committee’s Nov. 15 review of Heplisav for adults 18 to 70 years of age.

GSK’s Pandemic Vaccine Will Test Swine-To-Bird Approval Transmission

FDA agreed to infer GSK’s H5N1 vaccine’s effectiveness from the effectiveness of the adjuvanted H1N1 vaccine; agency’s Vaccines and Related Biological Products Advisory Committee will weigh in – and consider Dynavax’s hep B vaccine Heplisav – on Nov. 14.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS074572

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel